Goodwin Advises Ollin Biosciences on Oversubscribed $330 Million Series B Financing

Professionals

Kingsley L. TaftMaggie L. WongSwetha GopalakrishnanTheo HabouchaAshley Shultz

The Life Sciences team advised Ollin Biosciences, Inc., (Ollin) on an oversubscribed $330 million Series B financing. The financing round was co-led by new investor TCGX and founding investor ARCH Venture Partners, with participation from a syndicate of leading healthcare-focused crossover investors, sovereign wealth funds and other institutional investors new to Ollin, including a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., and a leading sovereign wealth fund, alongside continued investment from other co-founding investors Mubadala Capital and Monograph Capital.

Proceeds from the Series B financing will support the global Phase 3 development of OLN324, a next-generation VEGF/Ang2 bispecific antibody, in diabetic macular edema (DME) and wet (neovascular) age-related macular degeneration (wAMD), as well as the advancement of OLN102, a novel TSHR/IGF-1R bispecific antibody for thyroid eye disease (TED) and Graves’ disease, into clinical development this year.

Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology.

The Goodwin team was led by Maggie Wong, Theo Haboucha, and Kingsley Taft and included Swetha Gopalakrishnan, Ashley Shultz, and Ruowen Li.

For more information on the deal, please read the press release.

Goodwin Advises Ollin Biosciences on Oversubscribed $330 Million Series B Financing

Related Content

Xbrane Biopharma AB and JOINN Biologics US Inc. Partner to Develop Xdarzane

FDA Expands TOFIDENCE® (tocilizumab-bavi) Label to Include CRS and COVID-19

Teva Launches AHZANTIVE® Aflibercept Biosimilar in Europe

SEC Proposal Could Eliminate Baby Shelf Restrictions and Expand ATM Program Access For Smaller Companies

Royalty Monetization in an Era of Drug Pricing Pressure: How the IRA is Affecting Royalty Monetizations

Delaware is Enforcing Its Principal Place of Business Requirement: An Inaccurate Address Can Block Good Standing Certificates

Incyte to Acquire Vega Therapeutics, Adding Phase 3 Bleeding Disorder Asset

FDA Approves Lupin’s Ranibizumab Biosimilar

Goodwin Guides Triveni Bio on $65 Million Series C Financing

Goodwin Guides Tango Therapeutics in Upsized $690 Million Public Offering

Goodwin Represents Parabilis Medicines in Strategic Collaboration With Regeneron Pharmaceuticals for Up to $2.3 Billion

Goodwin Advises Engitix on Strategic Collaboration With GSK for £44.5 Million Upfront and Up to £118 Million in Milestones

Goodwin Guides Parabilis Medicines on Upsized $770.5 Million Initial Public Offering and $75 Million Private Placement to Regeneron Pharmaceuticals

Goodwin Guides City Therapeutics on $99.5 Million Series B Financing

Goodwin Advises Incyte in Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Incyte’s Hematology Portfolio into Bleeding Disorders

Goodwin Advises SonoThera on Oversubscribed $125 Million Series B Financing

Life Sciences

Life Sciences IPOs & Capital Markets